




RealRate

PHARMACEUTICAL 2015

Keryx Biopharmaceuticals INC
Rank 180 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Keryx Biopharmaceuticals INC is the variable Net Income, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 46% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	98,596
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	29,311
Liabilities, Non-Current	133
Other Assets	292
Other Compr. Net Income	0
Other Expenses	1,195
Other Liabilities	700
Other Net Income	11,236
Other Revenues	0
Property and Equipment	1,532
Research and Development	51,502
Selling, General and Administrative Expense	70,057

Output Variable	Value in 1000 USD
Assets	103,628
Liabilities	30,144
Expenses	122,754
Revenues	0
Stockholders Equity	73,484
Net Income	-111,518
Comprehensive Net Income	-111,518
BaseVar	133,881
ECR before LimitedLiability	73%
Economic Capital Ratio	208%